There is now robust evidence that lipoprotein(a) (Lp(a)) is independently and causally associated with increased risk of atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis.1,2 To address the need for novel approaches to reduce Lp(a), with the aim of achieving beneficial effects on cardiovascular outcomes, novel therapeutics are in development that target Lp(a). The Lp(a)-lowering effects of PCSK9 inhibitors have also been investigated.
View References
- Koutsogianni AD, Liamis G, Liberopoulos E et al. Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels-Potent Clinical Implications. Pharmaceuticals (Basel). 2023 May 16;16(5):750
- Kronenberg F, Mora S, Stroes ESG et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946.
